AstraZeneca

Open: 63.86 Close: 63.96 Change: 0.1

The 6 top things that an AI found about AstraZeneca Company Inc... they will surprise you

Are looking for the most relevant information about AstraZeneca? Investor spend a lot of time searching for information to make investment decisions in AstraZeneca. This task is often burdensome and consumes huge amounts of free time. It also leads to mistakes due to fatigue and bounded rationality. As a solution, we programmed an artificial intelligence that reads the whole internet and the uses natural language processing and vectorizers to summarize the information. Usually, the AI reads several hundred pages and summarize it to a short document. This document presents our results. We found that the most common words in the internet about AstraZeneca are: AstraZeneca, vaccine, company, drug, Astra, announce, disease, and the most common words in the summary are: astrazeneca, company, trial, news, vaccine, therapy, her2, . One of the sentences in the summary was: Average price target for AstraZeneca is $80.50, which is 25.86% higher than the current …

Concept Map

Semantic Network

Stock Summary

AstraZeneca PLC focuses on the discovery, development, manufacture, and commercialization of prescription medicines. Its marketed products include Calquence, Enhertu, Faslodex, Imfinzi, Iressa,.

Today's Summary

Astrazeneca PLC ADR AZN dropped 0.34% to $63.96 on Friday, underperforms market. Average price target for AstraZeneca is $80.50, which is 25.86% higher than the current price. Astrazenecas Covid-19 vaccine candidate, developed with the Britains University of Oxford, has resumed in the US.

Today's News

AstraZeneca traces its earliest corporate history to 1913. It has been involved in developing the Oxford–AstraZeneca COVID-19 vaccine. In 1999 Astra and Zeneca Group merged to form Astra. AstraZeneca announced it was spinning off six early-stage experimental drugs into a new biotechnology company, known as Viela Bio, valued at US$250 million. In July 2015, Genzyme announced it would acquire the rare cancer drug Caprelsa ( vandetanib ) from Astra Zeneca for US$300 million. AstraZeneca has its corporate headquarters in Cambridge, United Kingdom. Main research and development centres are in Cambridge (UK), Gaithersburg (Maryland, US), Gothenburg (Sweden) and Warsaw (Poland) In April 2015, drug tremelimumab was approved as an orphan drug for the treatment of mesothelioma. AstraZeneca plc 2022 Annual Report (Form 20-F). AstraZeneca buys rare disease drugmaker Caelum in potential $500 mln deal. Oxford vaccine researchers have found winning formula, AstraZevria chief says AstraZeneca to pay record 660% premium for gene editing company Astrazeneca PLC ADR AZN dropped 0.34% to $63.96 on Friday, underperforms market. AstraZeneca P.C. PLC closed $12.60 short of its 52-week high ($76.56), which the company achieved on April 25th. Astrazeneca bid to block medicare price talks barred, hhs says. AstraZeneca has a relatively large IR team of eight (including Barnett), allowing a ‘divide and conquer approach to the sell side. Barnett says investors in Shanghai and Tokyo proactively engage. AstraZeneca is best known for its contributions in the field of pharmaceuticals, particularly in oncology, respiratory diseases, cardiovascular health, and immunology. Astrazeneca has its headquarters in Cambridge, England, England. AstraZeneca has signed a joint research collaboration agreement with Cellectis to develop up to ten cell and gene therapy candidates. Cellectiss stock skyrocketed and was up by over 174% in pre-market trading. AstraZenecas Covid-19 vaccine candidate, developed with the Britains University of Oxford, has resumed in the US. Moderna CEO expects interim results from its Covid vaccine trial in November. Italy could have its first shots of Astrazenecas potential COVID-19 shot by end November. AstraZeneca has asked the FDA to allow adults ages 18 to 49 to be able to give themselves the flu vaccine. If approved, it would be the first flu vaccine cleared for self-administration. Average price target for AstraZeneca is $80.50, which is 25.86% higher than the current price. Astra has an Altman Z-Score of 2.68 and a Piotroski F-Scoring of 7.68. The company has a Long-Term Technical rank of 58. AstraZeneca has announced that its hyperkalaemia drug, Lokelma doubled the odds of maintaining lifesaving therapy in patients living with heart failure or kidney disease. The company has announced its potassium binder treatment has a 2.5 times increased chance of keeping patients within safe guidelines. AstraZeneca to invest $245 million in French biotechnology company Cellectis. Deal aimed at speeding up development of therapeutics in areas including oncology, immunology and rare diseases.

Stock Profile

"AstraZeneca PLC, a biopharmaceutical company, focuses on the discovery, development, manufacture, and commercialization of prescription medicines. The company's marketed products include Calquence, Enhertu, Faslodex, Imfinzi, Iressa, Koselugo, Lumoxiti, Lynparza, Orpathys, Tagrisso, and Zoladex for oncology; Andexxa/Ondexxya, Atacand, Atacand HCT, Atacand Plus, Brilinta/Brilique, Bydureon/Byetta, BCise, Byetta, Crestor, Evrenzo, Farxiga/Forxiga, Komboglyze/Kombiglyze XR, Lokelma, Onglyza, Qtern, Xigduo/Xigduo, and Zestril XR for cardiovascular, renal, and metabolism diseases; Accolate, Accoleit, Vanticon, Bevespi Aerosphere, Breztri Aerosphere, Bricanyl Respules and Turbuhaler, Daliresp/Daxas, Duaklir Genuair, Fasenra, Pulmicort, Rhinocort, Saphnelo, Symbicort, and Tezspire for respiratory and immunology; and Kanuma, Soliris, Strensiq, and Ultomiris for rare diseases. Its marketed products also comprise Synagis for respiratory syncytial virus; Fluenz Tetra/FluMist Quadrivalent for Influenza; and Vaxzevria and Evusheld for covid-19. The company serves primary care and specialty care physicians through distributors and local representative offices in the United Kingdom, rest of Europe, the Americas, Asia, Africa, and Australasia. It has a collaboration agreement with Neurimmune AG to develop and commercialize NI006; and Personalis, Inc. The company was formerly known as Zeneca Group PLC and changed its name to AstraZeneca PLC in April 1999. AstraZeneca PLC was incorporated in 1992 and is headquartered in Cambridge, the United Kingdom."

Keywords

The game is changing. There is a new strategy to evaluate AstraZeneca fundamental value, possible risks and most salient advantages. Investors have traditionally relied in reading large amounts of text to evaluate the fundamental value of a stock or company. However, the development of Artificial Intelligence (AI) tools is modifying the way investments are evaluated in markets. Today, machine learning, natural language processing and bigdata allow making this process automatic, reducing large amounts of text to the elements that have a higher activation in a neural network. We programmed an artificial intelligence that reads the whole internet and the uses natural language processing and vectorizers to summarize the information. Usually, the AI reads several hundred pages and summarize it to a short document. This document presents our results. We found that the most common words in the internet about AstraZeneca are: AstraZeneca, vaccine, company, drug, Astra, announce, disease, and the most common words in the summary are: astrazeneca, company, trial, news, vaccine, therapy, her2, . One of the sentences in the summary was: Average price target for AstraZeneca is $80.50, which is 25.86% higher than the current price. Other searches related to this term that the AI found were: stockmarketlive, livestock, stockmarketforbeginners, thestockmarket, stockmarkettoday, stockmarkettrading, stockmarketstocks, todaystockmarket, thestockmarket, marketnews, stockmarketnews, whatisstockmarket, usstockmarket, stockmarketopen. #astrazeneca #company #trial #news #vaccine #therapy #her2.